article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part III)

Practical Cheminformatics

Property Prediction Machine Learning Methods for Small Data Challenges in Molecular Science [link] Practical guidelines for the use of gradient boosting for molecular property prediction [link] Application of message passing neural networks for molecular property prediction [link] Molecular Similarity Molecular Similarity: Theory, Applications, and (..)

article thumbnail

Sygnature Discovery and Daewoong Pharma announce research collaboration

Sygnature Discovery

Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global healthcare group Daewoong Pharmaceutical to accelerate the discovery of a novel small molecule to target autoimmune disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues.

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

Data Science in Lead Optimization and Drug Design Data science accelerates the lead optimization and drug design process, transforming how molecules are engineered for therapeutic applications.

article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

The majority of small molecule drugs induce their therapeutic effects by seeking out and binding to their intended target while avoiding most other molecules in the dense milieu of the cell interior. Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA.

RNA 52
article thumbnail

Accelerating Innovation, Deepening Integration | Viva Biotech Online Investor Day Review

The Pharma Data

As well as continuously upgrading and optimizing existing 9 major technology platforms, Viva has also invested heavily in the fields of Cryo-EM, Computational Chemistry/Biology, etc. Dr. Xueheng Cheng, CTO of Viva Biotech, introduced the ASMS technology platform.

article thumbnail

Women in Stem with Dr Rachel Lagiakos

Drug Target Review

Working at the intersection of medicinal and computational chemistry as an early adopter of integrating in silico tools into the discovery process, I’ve seen first hand the technological advances that have been made over the past five-plus years.